Investigadors del grup de Gen\u00e8tica Molecular Humana de l’Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) liderats per la Dra. Sara Larriba, en col\u00b7laboraci\u00f3 amb el Dr. Francesc Vigu\u00e9s i el Dr. Manel Castells del Servei d’Urologia de l’Hospital Universitari de Bellvitge (HUB), mostren la utilitat de certes mol\u00e8cules, els miRNAs en semen, com a biomarcadors no invasius del c\u00e0ncer de pr\u00f2stata. Els resultats d’aquest estudi s’han protegit mitjan\u00e7ant una patent i es publiquen a Scientific Reports aquesta setmana.<\/p>\n
\u00a0<\/p>\n
El semen pot considerar-se com\u00a0la bi\u00f2psia l\u00edquida dels \u00f2rgans del sistema reproductor mascul\u00ed, i espec\u00edficament de la gl\u00e0ndula prost\u00e0tica: aproximadament el 40% del semen deriva del teixit prost\u00e0tic, de manera que \u00e9s probable que contingui mol\u00e8cules espec\u00edfiques derivades de la malaltia de la pr\u00f2stata. El grup de recerca de la Dra. Larriba, centrat en l’estudi de la l\u00ednia de recerca en “Gen\u00e8tica Molecular de la Infertilitat Masculina i C\u00e0ncer Urogenital”, ha determinat que la quantificaci\u00f3 de certes mol\u00e8cules d’\u00e0cid ribonucleic, conegudes com miRNAs, i que estan contingudes en ves\u00edcules extracel\u00b7lulars del plasma seminal, podrien ser cl\u00ednicament \u00fatils com a biomarcadors no invasius per al c\u00e0ncer de pr\u00f2stata.<\/p>\n
\u00a0<\/p>\n
“El nostre estudi mostra models basats en miRNAs d\u2019exosomes de semen com a biomarcadors moleculars amb el potencial de millorar l’efic\u00e0cia del diagn\u00f2stic i\/o pron\u00f2stic del c\u00e0ncer de pr\u00f2stata. Aquestes proves basades en miRNAs proporcionen informaci\u00f3 fiable que ajudar\u00e0 els metges a prendre decisions cl\u00edniques, i evitar\u00e0 bi\u00f2psies invasives innecess\u00e0ries per als pacients, millorant l’efici\u00e8ncia de la detecci\u00f3 del c\u00e0ncer de pr\u00f2stata i la qualitat assistencial del pacient\u201d, explica la Dra. Larriba.<\/p>\n
\u00a0<\/p>\n
El c\u00e0ncer de pr\u00f2stata \u00e9s el tipus de c\u00e0ncer mascul\u00ed maligne m\u00e9s freq\u00fcent en els pa\u00efsos occidentals. En els \u00faltims anys, s’ha aconseguit una disminuci\u00f3 significativa de la mortalitat gr\u00e0cies a l’\u00fas de PSA (antigen prost\u00e0tic espec\u00edfic) en sang com a marcador tumoral; per\u00f2, les defici\u00e8ncies de PSA com a biomarcador estan ben documentades: “En molts casos, tenir nivells elevats de PSA no vol dir presentar c\u00e0ncer de pr\u00f2stata, tamb\u00e9 s’associa a altres patologies com la hiperpl\u00e0sia benigna de pr\u00f2stata o la prostatitis. Per tant, l’examen de PSA ha resultat en un sobrediagn\u00f2stic de c\u00e0ncers de pr\u00f2stata i en moltes bi\u00f2psies innecess\u00e0ries de malaltia benigna “, comenta el Dr. Vigu\u00e9s.<\/p>\n
\u00a0<\/p>\n
“A m\u00e9s, els nivells s\u00e8rics de PSA no es correlacionen amb l’agressivitat del tumor, la superviv\u00e8ncia o la resposta als tractaments farmacol\u00f2gics, el que comporta a un tractament excessiu dels tumors no agressius. En aquest context, serien realment benvinguts biomarcadors no invasius m\u00e9s precisos per c\u00e0ncer de pr\u00f2stata amb fins de diagn\u00f2stic i pron\u00f2stic “, afegeix el Dr. Castells.<\/p>\n
\u00a0<\/p>\n
\u201dEl nostre objectiu \u00e9s oferir els nostres resultats a les cl\u00edniques com a prova de diagn\u00f2stic.\u00a0En aquest sentit, el seg\u00fcent pas \u00e9s la realitzaci\u00f3 d’estudis prospectius en cohorts m\u00e9s \u00e0mplies de pacients abans que aquest biomarcador basat en miRNAs pugui ser adoptat en la pr\u00e0ctica cl\u00ednica”, conclou Larriba.<\/p>\n","protected":false},"excerpt":{"rendered":"
Investigadors del grup de Gen\u00e8tica Molecular Humana de l’Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) liderats per la Dra. Sara Larriba, en col\u00b7laboraci\u00f3 amb el Dr. Francesc Vigu\u00e9s i el Dr. Manel Castells del Servei d’Urologia de l’Hospital Universitari de Bellvitge (HUB), mostren la utilitat de certes mol\u00e8cules, els miRNAs en semen, com a biomarcadors no […]<\/p>\n","protected":false},"author":6,"featured_media":10443,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[396,334],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-09 14:36:49","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7421"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7421"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10443"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}